Product logins

Find logins to all Clarivate products below.


Human Immunodeficiency Virus – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and total prevalence of HIV for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s HIV therapy forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HIV per year?
  • How will improvements in survival change the number of people living with HIV?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following HIV patient populations:

  • Diagnosed incident cases.
  • Total prevalent cases.
  • Total prevalent cases by diagnosis.
  • Diagnosed incident cases by treatment (mature pharmaceutical markets only).

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…